The loss of TP53 function either by the deletion of the short arm of chromosome 17 (del17p) or through inactivating mutations is a relatively common event in multiple myeloma (MM) and increases in frequency with disease progression [12,13,14,15]. The gene discussed is TP53; the disease is Miyoshi myopathy.